Contract development and manufacturing organisation (CDMO) Oxford Biomedica plc (OXB) (LON:OXB) on Tuesday announced the acquisition of a commercial-scale, FDA-approved viral vector manufacturing facility in Durham, North Carolina, from RTP Operating LLC, a subsidiary of National Resilience Holdco Inc.

The transaction, valued at USD4.5m (GBP3.4m) and funded from existing cash, aligns with OXB's strategy to expand its US GMP capacity and strengthen its global cell and gene therapy CDMO network.

The facility adds large-scale vector manufacturing and fill-finish capabilities, enhancing support for late-stage and commercial programmes, particularly in the adeno-associated virus (AAV) field. Located in the Research Triangle Park biopharma hub, the site provides access to a skilled workforce and established industry infrastructure.

OXB's new US site complements its existing operations in Oxford, Lyon, Strasbourg, and Bedford, Massachusetts, enabling multi-vector, multi-site manufacturing. Integration planning is underway, with key functions expected to be operational by the first quarter of 2026.

The acquisition is expected to generate a single-digit gain in 2025, offsetting associated transaction and operating costs. OXB plans further investment to bring the facility to full commercial readiness while maintaining its previously disclosed financial guidance and capital expenditure plans.